

ANTARES PHARMA, INC.  
Form 8-K  
June 11, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 6, 2012

**ANTARES PHARMA, INC.**

(Exact name of registrant specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**1-32302**  
(Commission  
File Number)

**41-1350192**  
(I.R.S. Employer  
Identification No.)

Edgar Filing: ANTARES PHARMA, INC. - Form 8-K

**100 Princeton South, Suite 300, Ewing, NJ**

**(Address of principal executive offices)**

**Registrant's telephone, including area code: (609) 359-3020**

**08628**

**(Zip Code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

On June 6, 2012 Antares Pharma, Inc. (the "Company") provided written notice to the NYSE Amex Exchange (the "NYSE Amex") that the Company plans to voluntarily transfer its common stock listing to The NASDAQ Stock Market LLC ("NASDAQ"). The Company's common stock, par value \$0.01 per share, has been approved for listing on NASDAQ and is expected to commence trading on NASDAQ on or about June 15, 2012 under the trading symbol "ATRS". The Company expects trading to cease on the NYSE Amex effective at the close of business on June 14, 2012.

A copy of the press release issued by the Company on June 6, 2012 is attached hereto as Exhibit 99.

**Item 9.01 Financial Statements and Exhibits.**

*(d) Exhibits*

(99) Press Release, dated June 6, 2012

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTARES PHARMA, INC.**

Date: June 11, 2012

By: /s/ Paul K. Wotton

Name: Dr. Paul K. Wotton

Title: President and Chief Executive Officer